Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ANI Pharmaceuticals (ANIP)

ANI Pharmaceuticals appoints Henry Gosebruch to board; director Samy Shanmugam resigns

Neutral Impact 3 of 5 leadership Written later

ANI Pharmaceuticals appointed Henry Gosebruch, former AbbVie strategy chief and former Neumora CEO, as a director effective August 19, 2026. Director Muthusamy Shanmugam resigned from the board on August 23, 2026, but remains an executive as Head of R&D and Chief Operating Officer of New Jersey Operations. The filing describes Gosebruch's role as supporting business development and capital allocation, which is relevant to shareholders as the company pursues its Rare Disease transformation.

Key points

  • Henry Gosebruch, 53, appointed to the Board with a term expiring at the 2027 annual meeting
  • Initial restricted stock award with a grant date fair value of $525,000, vesting in three equal annual installments
  • Samy Shanmugam resigned as a director effective immediately on August 23, 2026, and stays in his executive role

The filing

CompanyANI Pharmaceuticals (ANIP)
Form8-K, current report
Filed with the SECAug 24, 2026, 7:01 AM ET
Accession number0001023024-26-000071

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 24, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.